Cowen analyst Joseph Thome reiterated an Outperform rating and $130.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following news that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Axsome Therapeutics (AXSM) Rallies After Auvelity Gains FDA ApprovalAugust 19, 2022 2:13 PM Pre-Open Movers: Bed Bath Crashes on Cohen Sale, Foot Locker Jumps on New CEOAugust 19, 2022 9:18 AM Axsome's depression drug enters competitive market after U.S. approvalAugust 19, 2022 8:03 AM Axsome Therapeutics (AXSM) Climbs 40% Following FDA Approval of AUVELITYAugust 19, 2022 7:23 AM Form 8-K Axsome Therapeutics, For: Aug 19August 19, 2022 7:06 AM Axsome Therapeutics (AXSM) Announces FDA Approval of AUVELITYAugust 19, 2022 6:46 AM Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in AdultsAugust 19, 2022 6:46 AM